#ESMO26 | PANKU-Breast01 In HR+/HER2− mBC, the EGFR/HER3 bispecific ADC (iza-bren): PFS: 8.18 vs 4.05 months (HR 0.41). Grade ≥3 TRAEs: 40.5% vs 20.2%. OS remains immature. An impressive PFS benefit. However, in an era when ADCs such as T-DXd and SG are already in use, superiority over chemotherapy alone is not enough. Another treatment option… The added value of bispecific targeting, particularly its efficacy after other TOP1-ADCs, remains uncertain. These are the key data needed to define its place in treatment sequencing.